by Preliminary research conducted by Fairfield Market Research indicates a promising growth outlook for the global cancer gene therapy market over the next few years. Several key factors are contributing to this positive projection.
Exploding Rate of Cancer Prevalence Drives Market Growth
The global cancer gene therapy market is expected to witness substantial growth in the coming years, driven by factors such as increasing research and development investments, rising demand for DNA vaccines, improved regulatory standards, and growing ethical acceptance of gene therapy treatments for cancer. Supportive government regulations further enhance market opportunities. Notably, lower risks associated with cancer gene therapy and the integration of newly inserted genes into patients genomes without interfering with other genes activities are pivotal factors predicting market growth.
Rising Cancer Cases Worldwide
According to the Globocan 2020 fact sheet, the world witnessed approximately 9,958,133 cancer-related deaths and an estimated 19,292,789 new cancer cases. Projections suggest that by 2040, there will be 27.5 million new cancer cases and 16.3 million cancer-related deaths worldwide. The increasing prevalence of cancer underscores the need for advanced cancer medicines, driving the rapid growth of the cancer gene therapy market. Several companies are actively developing effective products, and the market is witnessing the emergence of small biopharma firms, such as Autolus Therapeutics, which specializes in gene therapies based on AAV.
COVID-19 Impact
The COVID-19 pandemic had a negative influence on the cancer gene therapy market, with a significant decline in cancer diagnoses during the pandemic. However, experts anticipate a recovery in the market as healthcare services normalize.
Rising Prevalence of Cancers Fuels Growth
The growing prevalence of cancer disorders, increased research focus on effective cancer treatments, and rising funding for cancer research are driving the cancer gene therapy market. Various gene therapy techniques are now employed to treat specific cancer types, including head and neck, skin, ovarian, lung, breast, pancreas, liver, colorectal, prostate, bladder, and renal cancer.
Improved Regulatory Environment
Enhanced regulatory standards are expected to expedite the growth of the cancer gene therapy market. Stringent regulations ensure the release of high-quality gene therapy products, boosting consumer confidence.
Cost Challenges
The high cost of cancer gene therapy may pose initial challenges, particularly in emerging economies. However, this is expected to be a short-term hurdle, with affordability increasing as wealth levels rise.
Gene-Induced Immunotherapy Dominates
Gene-induced immunotherapy is the leading segment in the cancer gene therapy market, driven by increased research funding, advancements in gene-induced immunotherapy research, and growing public awareness.
Breast Cancer Leads
Breast cancer is anticipated to dominate the cancer gene therapy market due to increased disease prevalence and government initiatives to boost cancer screening and diagnosis rates.
Regional Insights
North America leads the global cancer gene therapy market, driven by a concentration of key players, FDA approvals, strategic collaborations, and substantial R&D investments. Asia Pacific is expected to witness the fastest growth due to government measures promoting cancer gene therapy and improved healthcare infrastructure.
Competitive Landscape
Key players in the cancer gene therapy market include Merck KGaA, Novartis AG, AstraZeneca Plc., Bristol-Myers Squibb, and many others.
The future of the global cancer gene therapy market looks promising, with substantial growth potential driven by rising cancer cases and advancements in gene therapy techniques. As the market continues to evolve, innovative treatments and increased accessibility are expected to benefit patients worldwide.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/cancer-gene-therapy-market
Visit Our Blogs:
https://writeurl.com/3OuVCHdsSTR6ryZh
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
This press release first seen on Brilad
COMTEX_442430663/2840/2023-10-25T09:54:57
Julian Lopez is professor emeritus of finance, served as the founding academic affairs dean and founding chair of the finance department.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.